Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1504 participants.

Also called NCT01674647

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 1,504 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01674647
  • EudraCT 2011-002234-39
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Portugal, Singapore, South Africa, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01674647. Randomized; no masking; primary purpose prevention. Start 2012-10 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-02-03.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
Acronym
X-VERT
Intervention (Drug)
Rivaroxaban (Xarelto, BAY59-7939)
Intervention (Drug)
Vitamin K antagonist (VKA)
Lead sponsor
Bayer (class: industry)
Collaborator
Janssen Research & Development, LLC (class: industry)

Record details

Record id
cardio:ct-nct01674647
Content hash
8b2c7d8637e75c2dcf45d6c18a5ff40392a646375dc6e657f5da9bc9807473d2